Amgen and Xencor, Inc. have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The collaboration combines Amgen’s capabilities in target discovery and protein therapeutics with Xencor’s XmAb bispecific technology platform.   The collaboration includes Xencor’s molecular engineering and the preclinical development of bispecific molecules for five Amgen programs leveraging XmAb bispecific Fc dom...